A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Andrew Feigin, MD
The Marlene & Paolo Fresco Institute for Parkinson's & Movement Disorders-NYU Langone Medical Center
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
32 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Alberta
Edmonton, Alberta, Canada
- University of British Columbia
Vancouver, British Columbia, Canada
- Centre Hospitalier de L'Université de Montréal (chum)
Montreal, Quebec, Canada
- University of Alabama at Birmingham
Birmingham, Alabama, United States
- University of California, San Diego
La Jolla, California, United States
- University of California San Francisco
San Francisco, California, United States
- University of Colorado - Denver
Aurora, Colorado, United States
- Georgetown University
Washington D.C., District of Columbia, United States
- University of Florida Gainesville
Gainesville, Florida, United States
- Emory University School of Medicine
Atlanta, Georgia, United States
- Indiana University School of Medicine
Indianapolis, Indiana, United States
- University of Iowa
Iowa City, Iowa, United States
- University of Louisville
Louisville, Kentucky, United States
- Johns Hopkins University
Baltimore, Maryland, United States
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
- Massachusetts General Hospital
Charlestown, Massachusetts, United States
- University of Michigan
Ann Arbor, Michigan, United States
- Washington University
St Louis, Missouri, United States
- Columbia University
New York, New York, United States
- Columbia University
New York, New York, United States
- University of Rochester
Rochester, New York, United States
- Duke University Health Center
Durham, North Carolina, United States
- Wake Forest University
Winston-Salem, North Carolina, United States
- University of Cincinnati
Cincinnati, Ohio, United States
- Ohio State University
Columbus, Ohio, United States
- University of Toledo
Toledo, Ohio, United States
- Vanderbilt University
Nashville, Tennessee, United States
- University of Texas Houston Medical School
Houston, Texas, United States
- University of Vermont
Burlington, Vermont, United States
- Virginia Commonwealth University
Richmond, Virginia, United States
- University of Washington
Seattle, Washington, United States
- University of Washington and Va Puget Sound Health Care System
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2015
- Primary completion
- 31 Aug 2020
- Completion
- 31 Aug 2020
- Last update posted
- 2 May 2022
- Registered enrollment
- 301
- Registry id
- NCT02481674
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.